Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Metabolic disorders
Biotech
Aardvark halts obesity trials, putting entire pipeline on pause
The voluntary pause comes less than a month after Aardvark paused a phase 3 trial for a related asset due to cardiac concerns.
Darren Incorvaia
Mar 24, 2026 4:00am
Aardvark pauses ph. 3 hunger trial over 'cardiac observations'
Mar 2, 2026 4:40am
OrsoBio hits target in midstage study for metabolic conditions
Feb 10, 2026 8:00am
With 200 JPM meetings, Novo BD head seeks out the next Metsera
Jan 27, 2026 5:25pm
Qilu inks $120M, AI-enabled cardiometabolic pact with Insilico
Jan 27, 2026 5:20am
JPM: Novo CSO craves 'different flavors' of pipeline innovation
Jan 13, 2026 7:45am
